Idelalisib for the treatment of indolent non-hodgkin lymphoma: A review of its clinical potential

OncoTargets and Therapy

Volumn 9, Issue , 2016, Pages 2945-2953

  Barrientos, Jacqueline C ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

B cell receptor; Elderly; Follicular lymphoma; Kinase inhibitor; Phosphatidylinositol 3 kinase; Targeted therapy

Indexed keywords

BENDAMUSTINE; BRUTON TYROSINE KINASE INHIBITOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; GS 4059; IDELALISIB; LENALIDOMIDE; MITOXANTRONE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL TRIAL (TOPIC); COLITIS; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; FRAIL ELDERLY; HIGH RISK PATIENT; HUMAN; HYPERTRANSAMINASEMIA; INDOLENT NONHODGKIN LYMPHOMA; INTESTINE PERFORATION; LIVER TOXICITY; LONG TERM CARE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN BRUISING; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84969567683     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S102573     Document Type: Review

References (52)

1. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380(9844):848-857.
2. SEER. SEER Stat Fact Sheets: Non-Hodgkin Lymphoma. Bethesda, MD: National Cancer Institute; 2012.
3. Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008-1018.
4. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-276.
5. Lunning MA, Vose JM. Management of indolent lymphoma: where are we now and where are we going. Blood Rev. 2012;26(6):279-288.
6. Jaffe ES. Relationship of classification to biologic behavior of non-Hodgkin’s lymphomas. Semin Oncol. 1986;13(4 suppl 5):3-9.
7. Howlader N, Noone AM, Krapcho M, et al. [webpage on the Internet]. SEER Cancer Statistics Review, 1975-2012; 2015. Available from: http://seer.cancer.gov/csr/1975_2012/. Accessed October 6, 2015.
8. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol. 1993;20(5 suppl 5):75-88.
9. Trebouet A, Marchand T, Lemal R, et al. Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA. Ann Oncol. 2013;24(10):2612-2618.
10. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265.
11. Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516-2522.
12. Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111-1122.
13. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105(11):1684-1692.
14. Nabhan C, Smith SM, Helenowski I, et al. Analysis of very elderly ($80 years) non-Hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol. 2012;156(2):196-204.
15. National Comprehensive Cancer Network [webpage on the Internet]. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin’s Lymphomas (version 1.2015); 2015. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed October 6, 2015.
16. Hainsworth JD. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma: interim follow-up of a multicenter phase II trial. Semin Oncol. 2002;29(1 suppl 2):25-29.
17. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99(9):706-714.
18. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725-3732.
19. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004;22(23):4711-4716.
20. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417-1423.
21. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579-4586.
22. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203-1210.
23. American Cancer Society [webpage on the Internet]. Cancer Facts & Figures 2015. Available from: http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. Accessed March 31, 2015.
24. Casulo C, Burack WR, Friedberg JW. Transformed follicular non-Hodgkin lymphoma. Blood. 2015;125(1):40-47.
25. Press OW, Unger JM, Rimsza LM, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol. 2013;31(3):314-320.
26. Chao MP. Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma-novel and emerging therapies. Cancer Manage Res. 2013;5:251-269.
27. Nabhan C, Byrtek M, Rai A, et al. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. Br J Haematol. 2015;170(1):85-95.
28. Hiddemann W, Cheson BD. How we manage follicular lymphoma. Leukemia. 2014;28(7):1388-1395.
29. Vanhaesebroeck B, Welham MJ, Kotani K, et al. P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A. 1997;94(9):4330-4335.
30. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11(5):329-341.
31. Pauls SD, Lafarge ST, Landego I, Zhang T, Marshall AJ. The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions. Front Immunol. 2012;3:224.
32. Forcello N, Saraiya N. Idelalisib: the first-in-class phosphatidylinositol 3-kinase inhibitor for relapsed CLL, SLL, and indolent NHL. J Adv Pract Oncol. 2014;5:455-459.
33. Somoza JR, Koditek D, Villasenor AG, et al. Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase delta. J Biol Chem. 2015;290(13):8439-8446.
34. Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117(2):591-594.
35. ZYDELIG® (idelalisib tablets) [full prescribing information]. Foster City, CA: Gilead Sciences, Inc.; 2014.
36. European Medicines Agency [webpage on the Internet]. Idelalisib. Summary of Product Characteristics; 2014. Available from: https://www.medicines.org.uk/emc/medicine/29202. Accessed October 6, 2015.
37. Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123(22): 3406-3413.
38. de Vos S, Wagner-Johnston ND, Coutre SE, et al. Durable responses following treatment with the PI3K-delta inhibitor idelalisib in combination with rituximab, bendamustine, or both, in recurrent indolent non-Hodgkin lymphoma: phase I/II results. Blood. 2014;124(21): abstract3063.
39. Wagner-Johnston ND, Gopal AK, Kahl BS, et al. Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL). J Clin Oncol. 2014;32:e19554.
40. Smith N, Xenakis A, Beckerman R, Chhatwal J, Gregory SA, Briggs A. A decision-analytic model of idelalisib in relapsed or refractory patients with indolent non-Hodgkin lymphoma. J Clin Oncol. 2014;32:e17655.
41. Salles G, Schuster S, de Vos S, et al. Idelalisib efficacy and safety in follicular lymphoma patients from a phase 2 study. Paper presented at: 2015 American Society of Clinical Oncology Annual Meeting; May 28-June 3, 2015; Chicago, IL.
42. Barrientos J, Ghia P, Pagel J, et al. Outcomes of anticoagulant or antiplatelet use in patients with chronic lymphocytic leukemia or indolent non-hodgkin lymphoma in idelalisib trials. Paper presented at: ASCO Annual Meeting; May 29-June 2, 2015; Chicago, IL.
43. Coutre SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment-expert panel opinion. Leuk Lymphoma. 2015;56:1-20.
44. Lampson BL, Matos T, Kim HT, et al. Idelalisib given front-line for the treatment of chronic lymphocytic leukemia results in frequent and severe immune-mediated toxicities. Blood. 2015;126(23):497.
45. O’Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood. 2015;126(25):2686-2694.
46. Imbruvica® (ibrutinib capsules) [full prescribing information]. Horsham, PA: Janssen Biotech, Inc.; 2015.
47. Flinn I, Oki Y, Patel M, et al. A phase 1 evaluation of duvelisib (IPI-145), a PI3K-δ,γ inhibitor, in patients with relapsed/refractory iNHL. Blood. 2014;124(21):abstr802.
48. Dreyling M, Cunningham D, Bouabdallah K, et al. Phase 2A study of copanlisib, a novel PI3K inhibitor, in patients with indolent lymphoma. Blood. 2014;124(21):abstract1701.
49. Barr PM, Saylors GB, Forbes Spurgeon SE, et al. Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). J Clin Oncol. 2014;32(5s):abstract7059.
50. Smith SM, Pitcher B, Jung S-H, et al. Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: Alliance A051201 and A051202. Blood. 2014;124(21):3091.
51. Cheah CY, Nastoupil LJ, Neelapu SS, Forbes SG, Oki Y, Fowler NH. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood. 2015;125(21):3357-3359.
52. Zelenetz AD, Robak T, Coiffier B, et al. Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia: results of a phase 3 randomized double-blind placebo-controlled study. Blood. 2015;126(23):abstract LBA-5.